InspireMD Q3 loss narrows to $9.76M as revenue falls
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
InspireMD, Inc. (NSPR) reported third-quarter 2026 revenue of $2.242 million, versus $2.523 million a year earlier; gross profit was $240,000 versus $864,000, while net loss narrowed to $9.762 million from $12.708 million. For the first nine months, revenue was $7.411 million versus $5.830 million and net loss was $37.775 million versus $37.025 million. Operating cash use was $33.860 million versus $25.758 million.
Cash was $19.246 million as of September 30, 2026. The company disclosed substantial doubt about its ability to continue as a going concern, stating it lacked resources to fund operations for at least 12 months from issuance; it closed a November offering on November 16 for approximately $37.5 million in gross proceeds, before discounts, commissions and estimated expenses. The FDA approved CGuard Prime 80 cm on November 9. By September 30, all affected CGuard Prime 135 cm products in the voluntary U.S. recall had been returned and customer credits issued; the company recorded approximately $734,000 in revenue reductions and $612,000 of inventory impairment. It had a 180-calendar-day period, through January 13, 2027, to regain Nasdaq minimum bid-price compliance.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNine-month revenue: $7.411 million, versus $5.830 million.
- Moderate pointThird-quarter net loss: $9.762 million, versus $12.708 million.
- Minor pointCGuard Prime 80 cm received FDA approval on November 9, 2026.
Negative
- Major pointGoing-concern doubt: insufficient resources for at least 12 months.
- Moderate pointThird-quarter revenue: $2.242 million, versus $2.523 million.
- Moderate pointNine-month operating cash use: $33.860 million, versus $25.758 million.
- Moderate pointNasdaq bid-price compliance deadline: January 13, 2027.
- Moderate pointRecall impact: $734,000 revenue reduction and $612,000 inventory impairment.
Filing Explained
The lower exercise price leaves potential share issuance contingent on exercise; the amendments did not themselves issue shares.
On
If exercised, the amended warrants would add shares and reduce existing holders’ percentage ownership. Separately, 42,188,078 pre-funded warrants were outstanding at September 30; these convert into shares when exercised.
Following the
Key Figures
Key Terms
going concern financial
premarket approval regulatory
full ratchet anti-dilution adjustment financial
pre-funded warrants financial
Medical Device Regulation regulatory
fair value hierarchy financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were NSPR’s third-quarter 2026 results?
Why did NSPR report substantial doubt about its ability to continue as a going concern?
What does NSPR need to do to regain Nasdaq bid-price compliance?
Why was InspireMD’s CGuard Prime 135 cm recalled?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended:
OR
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission
file number:
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification No.) |
(Address of principal executive offices)
(Zip Code)
(Registrant’s telephone number, including area code)
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Smaller
reporting company | |
| Emerging
growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
The
number of shares of the registrant’s common stock, $
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
INSPIREMD, INC.
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF AND FOR THE QUARTER ENDED SEPTEMBER 30, 2026
TABLE OF CONTENTS
| Page | |
| CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED): | |
| Condensed Consolidated Balance Sheets | F-2 - F-3 |
| Condensed Consolidated Statements of Operations | F-4 |
| Condensed Consolidated Statements of Changes in Equity | F-5 - F-8 |
| Condensed Consolidated Statements of Cash Flows | F-9 |
| Notes to the Condensed Consolidated Financial Statements | F-10 - F-19 |
| F-1 |
INSPIREMD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(U.S. dollars in thousands, except share and per share data)
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Marketable securities | - | |||||||
| Accounts receivable: | ||||||||
| Trade, net | ||||||||
| Other | ||||||||
| Prepaid expenses | ||||||||
| Inventory | ||||||||
| TOTAL CURRENT ASSETS | ||||||||
| NON-CURRENT ASSETS: | ||||||||
| Long-term deposit | ||||||||
| Property, plant and equipment, net | ||||||||
| Operating lease right-of-use assets | ||||||||
| Fund in respect of employee rights upon retirement | ||||||||
| TOTAL NON-CURRENT ASSETS | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| F-2 |
INSPIREMD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(U.S. dollars in thousands except share and per share data)
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| LIABILITIES AND EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable and accruals: | ||||||||
| Trade | ||||||||
| Other | ||||||||
| TOTAL CURRENT LIABILITIES | ||||||||
| LONG-TERM LIABILITIES: | ||||||||
| Operating lease liabilities net of current maturities | ||||||||
| Liability for employee rights upon retirement and others | ||||||||
| TOTAL LONG-TERM LIABILITIES | ||||||||
| TOTAL LIABILITIES | ||||||||
| COMMITMENTS AND CONTINGENT LIABILITIES | - | - | ||||||
| EQUITY: | ||||||||
| Common stock, par value $ | ||||||||
| Preferred C shares, par value $ | -* | -* | ||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total equity | ||||||||
| Total liabilities and equity | $ | $ | ||||||
| * |
The accompanying notes are an integral part of the condensed consolidated financial statements.
| F-3 |
INSPIREMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(U.S. dollars in thousands, except share and per share data)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| REVENUES | $ | $ | $ | $ | ||||||||||||
| COST OF REVENUES | ||||||||||||||||
| GROSS PROFIT | ||||||||||||||||
| OPERATING EXPENSES: | ||||||||||||||||
| Research and development | ||||||||||||||||
| Selling and marketing | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Restructuring and other | - | - | ||||||||||||||
| Total operating expenses | ||||||||||||||||
| LOSS FROM OPERATIONS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| FINANCIAL INCOME, net: | ||||||||||||||||
| NET LOSS | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| NET LOSS PER SHARE - basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic and diluted | ||||||||||||||||
The accompanying notes are an integral part of the condensed consolidated financial statements.
| F-4 |
INSPIREMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)
(U.S. dollars in thousands, except share data)
| Shares | Amount | Shares | Amount | capital | deficit | equity | ||||||||||||||||||||||
| Common stock | Preferred
C shares | Additional paid-in | Accumulated | Total | ||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | capital | deficit | equity | ||||||||||||||||||||||
| BALANCE AT January 1, 2025 | -* | ( | ) | |||||||||||||||||||||||||
| Net loss | ( | ) | ( | ) | ||||||||||||||||||||||||
| Exercise of pre-funded warrants** | -* | - | - | - | -* | |||||||||||||||||||||||
| Issuance
of common stock, included at the market offering and pre-funded warrants net of $ | - | - | - | |||||||||||||||||||||||||
| Exercise
of Warrants Series I to | -* | - | - | - | ||||||||||||||||||||||||
| Share-based
compensation related to restricted stock, restricted stock units and stock option awards, net of forfeitures of | -* | - | - | - | ||||||||||||||||||||||||
| BALANCE AT September 30, 2025 | -* | ( | ) | |||||||||||||||||||||||||
| * |
| ** |
The accompanying notes are an integral part of the condensed consolidated financial statements.
| F-5 |
INSPIREMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)
(U.S. dollars in thousands, except share data)
| Shares | Amount | Shares | Amount | capital | deficit | equity | ||||||||||||||||||||||
| Common stock | Preferred
C shares | Additional paid-in | Accumulated | Total | ||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | capital | deficit | equity | ||||||||||||||||||||||
| BALANCE AT July 1, 2025 | -* | ( | ) | |||||||||||||||||||||||||
| Net loss | ( | ) | ( | ) | ||||||||||||||||||||||||
| Exercise of pre-funded warrants** | -* | - | - | - | - | -* | ||||||||||||||||||||||
| Exercise
of Warrants Series I to | -* | - | - | - | ||||||||||||||||||||||||
| Exercise of Warrants Series I to pre-funded warrants and common stock, net of issuance costs | -* | - | - | - | ||||||||||||||||||||||||
| Issuance
of common stock, included at the market offering and | - | - | - | |||||||||||||||||||||||||
| Issuance of common stock, included at the market offering and pre-funded warrants net of issuance costs | - | - | - | |||||||||||||||||||||||||
| Share-based
compensation related to restricted stock, restricted stock units and stock option awards, net of forfeitures of | -* | - | - | - | ||||||||||||||||||||||||
| BALANCE AT September 30, 2025 | -* | ( | ) | |||||||||||||||||||||||||
| * |
| ** |
The accompanying notes are an integral part of the condensed consolidated financial statements.
| F-6 |
INSPIREMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)
(U.S. dollars in thousands, except share data)
| Shares | Amount | Shares | Amount | capital | deficit | equity | ||||||||||||||||||||||
| Common stock | Preferred
C shares | Additional paid-in | Accumulated | Total | ||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | capital | deficit | equity | ||||||||||||||||||||||
| BALANCE AT January 1, 2026 | -* | ( | ) | |||||||||||||||||||||||||
| Net loss | ( | ) | ( | ) | ||||||||||||||||||||||||
| Issuance of common stock upon exercise of pre-funded warrants | -* | - | - | - | - | -* | ||||||||||||||||||||||
| Share-based
compensation related to restricted stock, restricted stock units and stock option awards, net of forfeitures of | - | - | - | |||||||||||||||||||||||||
| BALANCE AT September 30, 2026 | -* | ( | ) | |||||||||||||||||||||||||
| * |
The accompanying notes are an integral part of the condensed consolidated financial statements.
| F-7 |
INSPIREMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)
(U.S. dollars in thousands, except share data)
| Shares | Amount | Shares | Amount | capital | deficit | equity | ||||||||||||||||||||||
| Common stock | Preferred
C shares | Additional paid-in | Accumulated | Total | ||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | capital | deficit | equity | ||||||||||||||||||||||
| BALANCE AT July 1, 2026 |
-* | ( | ) | |||||||||||||||||||||||||
| Balance |
-* | ( | ) | |||||||||||||||||||||||||
| Net loss | ( | ) | ( | ) | ||||||||||||||||||||||||
| Issuance of common stock upon exercise of pre-funded warrants | -* | - | - | - | - | -* | ||||||||||||||||||||||
| Share-based
compensation related to restricted stock, restricted stock units and stock option awards, net of forfeitures of | ( | ) | -* | - | - | - | ||||||||||||||||||||||
| Share-based compensation related to restricted stock, restricted stock units and stock option awards, net of forfeitures | ( | ) | -* | - | - | - | ||||||||||||||||||||||
| BALANCE AT September 30, 2026 | -* | ( | ) | |||||||||||||||||||||||||
| Balance | -* | ( | ) | |||||||||||||||||||||||||
| * |
The accompanying notes are an integral part of the condensed consolidated financial statements.
| F-8 |
INSPIREMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(U.S. dollars in thousands)
| 2026 | 2025 | |||||||
| Nine
months ended September 30 | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | ||||||||
| Gain from sale of property, plant and equipment | - | ( | ) | |||||
| Change in fair value of marketable securities, net of interest received | ( | ) | ||||||
| Change in liability for employee rights upon retirement | ||||||||
| Other financial income | ( | ) | ( | ) | ||||
| Change in operating right of use asset and operating leasing liability | ( | ) | ||||||
| Share-based compensation expenses | ||||||||
| Gain on amounts funded in respect of employee rights upon retirement, net | ( | ) | ( | ) | ||||
| Changes in operating assets and liability items: | ||||||||
| Decrease in prepaid expenses | ||||||||
| Decrease (increase) in trade receivables | ( | ) | ||||||
| Decrease (increase) in other receivables | ( | ) | ||||||
| Decrease (increase) in inventory | ( | ) | ||||||
| Increase in trade payables | ||||||||
| Increase (decrease) in other payables | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchase of property, plant and equipment | ( | ) | ( | ) | ||||
| Proceeds from sale of property, plant and equipment | - | |||||||
| Investments in marketable securities | - | ( | ) | |||||
| Proceeds from matured marketable securities | ||||||||
| Amounts funded in respect of employee rights upon retirement | ( | ) | ( | ) | ||||
| Net cash provided by investing activities | ||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from exercise of warrants | - | |||||||
| Proceeds
from issuance of shares and pre-funded warrants, net of $ | - | |||||||
| Net cash provided by financing activities | - | |||||||
| EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | ||||||||
| INCREASE IN CASH AND CASH EQUIVALENTS | ||||||||
| BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD | ||||||||
| BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE PERIOD | $ | $ | ||||||
| SUPPLEMENT NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
| Acquisition of right-of-use
assets by means of lease liabilities | - | |||||||
| Non-cash purchase of property and equipment | ||||||||
The accompanying notes are an integral part of the condensed consolidated financial statements.
| F-9 |
INSPIREMD, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 - DESCRIPTION OF BUSINESS
| a. | General | |
InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries in Israel and Germany, is a medical device company specializing in the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions. The Company’s portfolio includes two commercial platforms based on its proprietary CGuard™ carotid stent technology, designed to provide market-leading embolic protection during and after stenting procedures. A stent is an expandable scaffold-like metallic device placed in an artery to widen the lumen and restore blood flow. | ||
| The Company’s first platform, the CGuard™ Carotid Embolic Prevention System (“CGuard EPS”), integrates a self-expanding nitinol stent with a MicroNet™ mesh sleeve as a single device for carotid artery revascularization. The Company has received CE Mark recertification for CGuard EPS under the EU Medical Device Regulation (“MDR”). The Company’s CGuard EPS previously held CE Mark approval under the former Medical Device Directive (“MDD”). CGuard EPS is marketed in over 30 countries outside the United States, mainly in Europe, through a network of distributors. In the first quarter of 2026, the Company submitted a premarket approval (“PMA”) to the U.S. Food and Drug Administration (“FDA”) for the CGuard EPS. | ||
The Company’s second platform, the CGuard™ Prime Carotid Stent System (“CGuard Prime”), uses the same stent and MicroNet mesh with a differentiated deployment mechanism. CGuard Prime for use in carotid artery stenting (“CAS”) procedures (“CGuard Prime 135 cm”) received PMA by the FDA on June 23, 2025. CGuard Prime 135 cm also received MDR CE Mark approval on June 12, 2025. CGuard Prime for use in transcarotid artery revascularization (“TCAR”) procedures (“CGuard Prime 80 cm”) received PMA by the FDA on November 9, 2026, see note 7(d).
In May 2026, the Company announced a voluntary recall in the U.S. of CGuard Prime 135 cm, initiated in consultation with the FDA after the Company determined during a controlled launch that the technical success rate of its delivery system did not meet performance expectations. The voluntary action was limited to the CGuard Prime 135 cm delivery system and did not involve the CGuard stent implant. The Company’s assessment did not identify new safety concerns for patients who had previously received a CGuard implant. | ||
As
of September 30, 2026, all affected products were returned and credits were issued to customers.
The Company recorded approximately $ |
| F-10 |
| b. | Liquidity
| |
The Company has an accumulated deficit as of September 30, 2026, as well as a history of net losses and negative operating cash flows. The Company expects to continue incurring losses and negative cash flows from operations until the Company expands its commercial revenue to a scale that funds its commercial resources, development activities and support functions. As a result of these expected losses and negative cash flows from operations, along with the Company’s current cash position, the Company does not have sufficient resources to fund operations for at least the next 12 months from the date these condensed consolidated financial statements are issued. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.
On
November 16, 2026, the Company closed the November 2026 Offering, as described in Note 15a, resulting in gross proceeds of approximately
$
On July 17, 2026, the Company received a notification letter from the Nasdaq Listing Qualifications notifying the Company that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until January 13, 2027, to regain compliance. If the Company does not regain compliance by that date, it may be eligible for an additional 180 calendar day compliance period, subject to satisfying certain continued listing and initial listing requirements. If the Company does not regain compliance within the applicable compliance period, its common stock would be subject to delisting from The Nasdaq Capital Market, which could adversely affect the Company’s ability to raise additional capital.
Management’s plans include the continued commercialization of the Company’s products and raising capital through the sale of additional equity securities, debt or capital inflows from potential strategic partnerships and exercises of warrants. There are no assurances, however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it may need to reduce activities, curtail or cease operations. | ||
| c. | Risks Related to the Company’s Operations in Israel
| |
On October 7, 2023, Hamas launched a series of attacks on civilian and military targets in Southern Israel and Central Israel, to which the Israel Defense Forces responded. In addition, Iran, Hezbollah and the Houthi movement attacked military and civilian targets in Israel, to which Israel responded, including through increased air and/or ground operations in Lebanon, Syria, Yemen and Iran. On October 9, 2025, Israel, Hamas, the United States and other countries in the region agreed to a framework for a ceasefire in Gaza between Israel and Hamas. On February 28, 2026, the United States and Israel launched joint combat operations in Iran, to which Iran and Hezbollah responded with ballistic missile and drone attacks on Israel, as well as on other countries and U.S. military bases in the region. Although the United States and Iran have announced ceasefire and de-escalation arrangements from time to time, including a memorandum of understanding entered into on June 17, 2026 that contemplates the termination of military operations on multiple fronts, hostilities have resumed and may continue or escalate. A broader regional conflict involving additional state and non-state actors remains a significant risk. The duration and severity of the conflicts in Gaza, northern Israel, Lebanon, Iran and the broader region are unknown at this time, and any renewed or continued clash among Israel, Hamas, Hezbollah, Iran or other countries or militant groups in the region may escalate in the future into a greater regional conflict. Continued military escalation, retaliatory actions, or broader regional involvement may adversely affect economic conditions, disrupt markets, and create uncertainty that could negatively impact the Company’s business, financial condition and results of operations. As of the date of these condensed consolidated financial statements, conflict continues in parts of the region. The Company’s current manufacturing facility, certain of its key personnel and one of its offices are located in Israel. At this time, these activities remain largely unaffected.
| ||
| During the three and nine months ended September 30, 2026 and 2025, the impact of these conflicts on the Company’s results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of these conflicts. |
| F-11 |
NOTE 2 - BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of the Company, the financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of its financial position as of September 30, 2026, and its results of operations, changes in equity and cash flows for the three and nine months ended September 30, 2026, and 2025. These unaudited condensed consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2025, as found in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 18, 2026. The results of operations for the nine and three months ended September 30, 2026, are not necessarily indicative of results that could be expected for the entire fiscal year.
NOTE 3 - RECENTLY ADOPTED AND ISSUED ACCOUNTING PRONOUNCEMENTS
Recently issued accounting pronouncement, not yet adopted
In November 2024, the FASB issued ASU No. 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures about a public business entity’s expense and provides more detailed information about the types of expenses in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory, employee compensation, depreciation and amortization included in each relevant expense caption (such as cost of sales, G&A, S&M and research and development) as well as disclosures about selling expenses. The ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating this ASU to determine its impact on the Company’s consolidated financial statements and disclosures.
NOTE 4 - FAIR VALUE MEASUREMENTS
Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.
Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
| F-12 |
The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:
SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
As of September 30, 2026 ($ in thousands) | ||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
| Assets: | ||||||||||||||||
| Cash equivalents- | ||||||||||||||||
| Money market funds | $ | $ | $ | - | $ | - | ||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
As of December 31, 2025 ($ in thousands) | ||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
| Assets: | ||||||||||||||||
| Cash equivalents- | ||||||||||||||||
| Money market funds | $ | $ | $ | - | $ | - | ||||||||||
| Marketable securities- | ||||||||||||||||
| U.S. government bonds | $ | $ | - | $ | $ | - | ||||||||||
The Company’s cash equivalents, and marketable securities are classified within Level 1 and Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.
The
cost of marketable securities as of December 31, 2025, is $
| F-13 |
NOTE 5 - MARKETABLE SECURITIES
As of the end of the quarter, all securities had already matured.
The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the nine-month period ended September 30, 2026, and 2025:
SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES
| 2026 | 2025 | |||||||
Nine months ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| ($ in thousands) | ||||||||
| Balance at beginning of the period | $ | $ | ||||||
| Additions | - | |||||||
| Maturity | ( | ) | ( | ) | ||||
| Interest received | ( | ) | ( | ) | ||||
| Changes in fair value during the period | ||||||||
| Balance at end of the period | - | - | ||||||
NOTE 6 - RESTRUCTURING AND OTHER CHARGES
During the third quarter of 2026, the Company approved and completed a workforce reduction and efficiency plan designed to align its operating structure and cost base with its strategic priorities. The plan included employee terminations in the United States and certain EMEA countries, together with related separation, benefit-continuation, outplacement and directly attributable advisory activities.
For
the three and nine months ended September 30, 2026, the Company recognized restructuring and related charges of $
| F-14 |
The following table summarizes the charges recognized under the plan (in thousands):
SCHEDULE OF RESTRUCTURING AND OTHER CHARGES
Three months ended September 30, 2026 | Nine months ended September 30, 2026 | |||||||
| One-time involuntary termination benefits (ASC 420) | $ | $ | ||||||
| Statutory and contractual termination benefits (ASC 712) | $ | $ | ||||||
| Total employee termination and separation benefits | $ | $ | ||||||
| Legal and advisory fees and other restructuring costs | $ | $ | ||||||
| Total restructuring and related charges | $ | $ | ||||||
The following table summarizes activity in the restructuring-related liability (in thousands):
SCHEDULE OF ACTIVITY IN RESTRUCTURING RELATED ACTIVITY
| Liability activity | Nine months September 30, 2026 | |||
| Balance on January 1, 2026 | $ | — | ||
| One-time involuntary termination charges (ASC 420) | ||||
| Statutory and contractual termination charges (ASC 712) | ||||
| Total employee termination and separation charges | ||||
| Cash payments | ( | ) | ||
| Balance on September 30, 2026 | $ | |||
The remaining liability is included in accounts payable and accruals—other and is expected to be settled within six months. Legal and advisory fees and outplacement costs are expensed as incurred and therefore are not included in the liability rollforward.
NOTE 7 - EQUITY
| a. | Authorized Capital Stock | |
| As
of September 30, 2026, the Company had | ||
| b. | Preferred Stock | |
As
of September 30, 2026, there were
Pursuant to the full ratchet anti-dilution adjustment
provisions in the certificate of designation for the Company’s Series C preferred stock, following the Warrant Amendments described
in Note 7d, the conversion price of the outstanding shares of Series C preferred stock was reduced from $
| ||
| c. | Pre-Funded Warrants | |
| As
of September 30, 2026, there were |
| F-15 |
| d. | Warrants | |
| On
September 21, 2026, the Company entered into amendments (the “Warrant Amendments”) with certain holders of its outstanding
Series J and Series K warrants (collectively, the “Existing Warrants”). Pursuant to the Warrant Amendments, the Company
amended Series J warrants covering | ||
The
Company accounted for the Warrant Amendments as modifications of equity-classified warrants
and measured the modification effect as the excess of fair value immediately after modification
over fair value immediately before modification. The resulting incremental fair value of
$
As
of September 30, 2026, the Company has outstanding warrants to purchase an aggregate of |
SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK
| Classification | Series J | Series K | Total warrants amount | Exercise price | Expiration date | |||||||||||||||
| Amended | $ | |||||||||||||||||||
| Unamended | $ | |||||||||||||||||||
| Total | — | — | ||||||||||||||||||
| * |
Unamended Series J warrants: expire on the earlier of May 15, 2028 and 20 trading days following the Company’s announcement of receipt of FDA approval for SwitchGuard and CGuard Prime 80 cm.
Unamended Series K warrants: expire on the earlier of May 15, 2028 and 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of CGuard Prime 135 cm in the U.S. began. Subsequent to that date, the unamended Series K warrants expired unexercised on October 28, 2026.
On November 12, 2026, the Company announced FDA approval for CGuard Prime 80 cm. Accordingly, the amended Series
J warrants and amended Series K warrants will expire on
During
the nine months ended September 30, 2026, a total of
| e. | Share-Based Compensation | |
| During
the nine months ended September 30, 2026, the Company granted | ||
| The
fair value of the above restricted shares was approximately $ | ||
During
the nine months ended September 30, 2026, the Company granted | ||
| The
fair value of the above restricted stock units was approximately $ |
| F-16 |
NOTE 8 - RELATED PARTY TRANSACTIONS
During
the three and nine months ended September 30, 2025, administrative services provided by a member of the chief executive officer’s
immediate family in connection with the Company’s expansion to the U.S. amounted to $
NOTE 9 - NET LOSS PER SHARE
Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock, pre-funded warrants and fully vested restricted stock units outstanding during the period. The calculation of diluted net loss per share excludes the potentially dilutive effects of share options, warrants, unvested restricted stock, unvested restricted stock units and Series C preferred stock because their effects are anti-dilutive.
For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration, as determined by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them.
The
total numbers of shares of common stock underlying outstanding options, warrants, unvested restricted stock, unvested restricted stock
units and Series C preferred stock excluded from the calculation of diluted net loss per share were
For the three and nine months ended September 30, 2026, and 2025, the weighted average number of common stock used in computing net loss per share - basic and diluted was as follows:
SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Three
months ended | Nine
months ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Weighted average number of common stock | ||||||||||||||||
| Weighted average vested restricted stock units | ||||||||||||||||
| Weighted average pre-funded warrants | ||||||||||||||||
| Total weighted average number of common shares used in computing net loss per share (basic and diluted) | ||||||||||||||||
During
the three and nine months ended September 30, 2026, the Company recognized a deemed dividend of approximately $
| F-17 |
The following table presents the reconciliation of net loss to net loss available to common stockholders after giving effect to the deemed dividend:
SCHEDULE OF RECONCILIATION OF NET LOSS AVAILABLE TO COMMON STOCKHOLDERS
| (U.S. dollars in thousands) | Three months ended September 30, 2026 | Nine months ended September 30, 2026 | ||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Deemed dividend | ( | ) | ( | ) | ||||
| Net loss available to common stockholders | $ | ( | ) | $ | ( | ) | ||
NOTE 10 - FINANCIAL INSTRUMENTS
| a. | Fair value of financial instruments | |
| As of September 30, 2026, and December 31, 2025, the carrying amounts of accounts payable, accounts receivable and other receivables approximate their fair values due to the short-term maturities of these instruments. | ||
| The carrying amount of the long-term deposit approximates its fair value since it is measured at its present value applying prevailing interest rates. | ||
| b. | As of September 30, 2026, and December 31, 2025, the allowance for expected credit loss was immaterial. |
NOTE 11 - INVENTORY:
SCHEDULE OF INVENTORIES
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| ($ in thousands) | ||||||||
| Finished goods | $ | $ | ||||||
| Work in process | ||||||||
| Raw materials and supplies | ||||||||
| Total inventory | $ | $ | ||||||
| * | The Company recorded
approximately $ |
NOTE 12 - ACCOUNTS PAYABLE AND ACCRUALS – OTHER
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| ($ in thousands) | ||||||||
| Employees and employee institutions | $ | $ | ||||||
| Accrued vacation and recreation pay | ||||||||
| Accrued expenses | ||||||||
| Clinical trial accrual | ||||||||
| Current Operating lease liabilities | ||||||||
| Customer credit balances* | ||||||||
| Other | ||||||||
| Accounts Payable and Accruals - Other | $ | $ | ||||||
| * |
NOTE 13 - DISAGGREGATED REVENUE AND ENTITY-WIDE DISCLOSURES
Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues:
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three
months ended September 30, | Nine
months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| ($ in thousands) | ||||||||||||||||
| Germany | $ | $ | $ | $ | ||||||||||||
| Italy | ||||||||||||||||
| Poland | ||||||||||||||||
| USA** | ||||||||||||||||
| Other* | ||||||||||||||||
| Revenues | $ | $ | $ | $ | ||||||||||||
| * |
| ** |
| F-18 |
By principal customers (part of revenues):
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three
months ended September 30, | Nine
months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Customer A | % | % | % | % | ||||||||||||
| Customer B | % | % | % | % | ||||||||||||
NOTE 14 - SEGMENT INFORMATION
The
Company has
The CODM examines, within each operational function, the employee salaries including the bonus and share based compensation. In addition, the CODM examines the clinical trials expenses within the research and development operations.
SCHEDULE OF SEGMENT REVENUE
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three
months ended September 30, | Nine
months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues | ||||||||||||||||
| Cost of Revenues: | ||||||||||||||||
| Material and Labor | ||||||||||||||||
| Other cost of revenues | ||||||||||||||||
| Inventory write-off | - | - | - | |||||||||||||
| Total Cost of Revenues | ||||||||||||||||
| Research and development (R&D) | ||||||||||||||||
| Payroll and Benefits | ||||||||||||||||
| Share based compensation | ( | ) | ||||||||||||||
| Clinical trials | ||||||||||||||||
| Other R&D | ||||||||||||||||
| Total Research and development | ||||||||||||||||
| Selling and marketing (S&M) | ||||||||||||||||
| Payroll and Benefits | ||||||||||||||||
| Share based compensation | ( | ) | ||||||||||||||
| Other S&M | ||||||||||||||||
| Total Selling and marketing | ||||||||||||||||
| General and administrative (G&A) | ||||||||||||||||
| Payroll and Benefits | ||||||||||||||||
| Share based compensation | ||||||||||||||||
| Other G&A | ||||||||||||||||
| Total General and administrative | ||||||||||||||||
| Total Restructuring | - | - | ||||||||||||||
| Financial Income (expenses), net; | ||||||||||||||||
| Segment net loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
NOTE 15 - SUBSEQUENT EVENTS:
| a. | Subsequent
to September 30, 2026, on November 13, 2026, the Company entered into an underwriting agreement
(the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as representative
(the “Representative”) of the several underwriters named therein (collectively,
the “Underwriters”), relating to the issuance and sale in an underwritten public
offering (the “November 2026 Offering”) of (i) |
The
November 2026 Offering closed on November 16, 2026. The gross proceeds from the November 2026 Offering were approximately $
Each
November 2026 Pre-Funded Warrant has an exercise price of $
The
Company also granted the Representative a 30-day option to purchase up to
| b. | Pursuant
to the full ratchet anti-dilution adjustment provisions in the certificate of designation
for the Company’s Series C preferred stock, following the November 2026 Offering described
in Note 15a, the conversion price of the outstanding shares of Series C preferred stock was
reduced from $ |
| F-19 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q.
Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to the “Company,” “InspireMD,” “we,” “our” and “us” refer to InspireMD, Inc., a Delaware corporation, and its subsidiaries.
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which include information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation, including revenue growth. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or our management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:
| ● | our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives, and substantial doubt regarding our ability to continue as a going concern; | |
| ● | our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute our stockholders’ ownership interests; | |
| ● | the clinical development, commercialization and market acceptance of our products; | |
| ● | whether the clinical trial results for our products will be predictive of real-world results; | |
| ● | an inability to secure and maintain regulatory approvals for the sale of our products; | |
| ● | any impact of a product recall, including the voluntary recall in the U.S. of the CGuard Prime 135cm Carotid Stent System, or any future product recall, on our business, results of operations and financial condition; | |
| ● | negative clinical trial results or lengthy product delays in key markets; | |
| ● | our ability to maintain compliance with the Nasdaq listing standards; | |
| ● | our ability to generate significant revenues from our products; | |
| ● | estimates of our expenses, future revenues, capital requirements and our needs for and ability to access sufficient additional financing, including any unexpected costs or delays in resuming U.S. commercialization of CGuard Prime following the voluntary recall or in the commercial launch of our other products; | |
| ● | our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; | |
| ● | the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; |
| ● | intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; | |
| ● | entry of new competitors and products and potential technological obsolescence of our products; | |
| ● | inability to carry out research, development and commercialization plans; | |
| ● | loss of a key customer or supplier; | |
| ● | technical problems with our research and products and potential product liability claims; | |
| ● | product malfunctions; | |
| ● | price increases for supplies and components; | |
| ● | whether access to our products is achieved in a commercially viable manner and whether our products receive adequate reimbursement by governmental and other third-party payers; | |
| ● | our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; | |
| ● | adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; | |
| ● | the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; |
| 2 |
| ● | security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel; | |
| ● | current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; and | |
| ● | changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements and the impact of such policies on us, our customers and suppliers, and the global economic environment. |
The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we face that may cause our actual results to differ from those anticipated in our forward-looking statements. For a discussion of these and other risks that relate to our business and investing in our common stock, you should carefully review the risks and uncertainties described under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2026, in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our subsequent reports filed with the SEC. The forward-looking statements contained in this Quarterly Report on Form 10-Q are expressly qualified in their entirety by this cautionary statement. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Overview
We are a medical device company specializing in the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions. Our portfolio includes two commercial platforms based on our proprietary CGuard carotid stent technology, designed to provide market-leading embolic protection during and after stenting procedures. A stent is an expandable scaffold-like metallic device placed in an artery to widen the lumen and restore blood flow.
Our first platform, the CGuard Carotid Embolic Prevention System (“CGuard EPS”), integrates a self-expanding nitinol stent with a MicroNet mesh sleeve as a single device for carotid artery revascularization. In January 2024, we received CE Mark recertification for CGuard EPS under the EU Medical Device Regulation (“MDR”). Our CGuard EPS previously held CE Mark approval under the former Medical Device Directive (“MDD”). CGuard EPS is marketed in over 30 countries outside the United States through a network of distributors. In the first quarter of 2026, we submitted a premarket approval application to the U.S. Food and Drug Administration (“FDA”) for CGuard EPS with potential for FDA approval in the fourth quarter of 2026.
Our second platform, the CGuard Prime Carotid Stent System (“CGuard Prime”), uses the same stent and MicroNet mesh as CGuard EPS with a differentiated deployment mechanism. We have two distinct products within the CGuard Prime platform for use in different procedures to implant the stent. The first product was designed for use in carotid artery stenting (“CAS”) procedures and utilizes a 135 cm catheter as part of the delivery system (“CGuard Prime 135 cm”). The second product was designed for use during transcarotid artery revascularization (“TCAR”) procedures and utilizes a shorter 80 cm catheter in its delivery system (“CGuard Prime 80 cm”).
CGuard Prime 135 cm received premarket approval (“PMA”) from the FDA on June 23, 2025 and MDR CE Mark approval on June 12, 2025 for use in CAS procedures. In May 2026, we announced a voluntary recall in the U.S. of CGuard Prime, undertaken in consultation with the FDA after a controlled launch demonstrated that the technical success of its delivery system did not meet performance expectations. The voluntary action pertained specifically to the delivery system and not to the CGuard Prime stent implant. For additional information, see “FDA Matters” below.
In October 2024, the FDA approved our investigational device exemption (“IDE”) application to initiate the CGUARDIANS II pivotal study of the CGuard Prime TransCarotid Stent System during transcarotid artery revascularization (“TCAR”) procedures. In the first quarter of 2026, we completed enrollment in the CGUARDIANS II pivotal study, and in June 2026, we announced summary 30-day outcome data from the study, which showed acute device success of 100% with no major adverse events.
| 3 |
CGuard Prime 80 cm received premarket approval (“PMA”) from the FDA on November 9, 2026 for use in TCAR procedures. We have commercial inventory of CGuard Prime 80 cm prepared for commercial launch and expect to commence sales promptly in the fourth quarter of 2026.
In May 2026, we announced that the FDA had approved our IDE application to initiate the CGUARDIANS III pivotal trial, which evaluates our proprietary SwitchGuard neuroprotection system (“SwitchGuard NPS”) paired with the CGuard Prime TransCarotid Stent System to enable flow-reversal neuroprotection during TCAR, and in June 2026, we announced enrollment of the first patient.
In October 2023, the Centers for Medicare & Medicaid Services (“CMS”) issued its final National Coverage Determination (“NCD”), expanding coverage for both CAS and TCAR procedures to include both asymptomatic and standard surgical risk patients, which we believe significantly expands and supports the future growth of the U.S. addressable market for CAS.
In November 2025, the results of the CREST-2 study were released, which showed that CAS combined with medical therapy demonstrated a significantly lower stroke risk as compared to intensive medical management alone in patients with severe asymptomatic carotid stenosis. CREST-2 was an independent study sponsored by the National Institutes of Health (“NIH”) with a set of two parallel, observer-blinded clinical trials across 155 centers globally. CREST-2 showed that, among patients with high-grade carotid stenosis without recent neurological symptoms, the addition of stenting led to significantly better outcomes than intensive medical management alone, as measured by a decreased risk of the composite of perioperative stroke or death or ipsilateral stroke within four years. In a separate arm of the same trial, carotid endarterectomy (“CEA”) did not achieve a significant benefit for these patients as compared to intensive medical management alone.
We continue to invest in new product generations and potential new clinical indications for the CGuard platform with a strategy of focusing on advancing a “stent-first” approach to carotid revascularization. As part of this strategy, we are evaluating the CGuard Prime TransCarotid Stent System in TCAR-based clinical programs, including the CGUARDIANS II pivotal trial, which studied the use of the CGuard Prime TransCarotid Stent System in conjunction with an established neuroprotection device, and the CGUARDIANS III pivotal trial, which evaluates our proprietary SwitchGuard neuroprotection system paired with the CGuard Prime TransCarotid Stent System to enable flow-reversal neuroprotection during TCAR. In parallel, we are pursuing new clinical applications outside TCAR, including the treatment of acute ischemic stroke with tandem lesions. In this acute-stroke setting, the flexible, low-metal-burden design and MicroNet mesh of the CGuard Prime Carotid Stent may offer advantages where traditional embolic-protection devices cannot be used. We initially partnered with Jacobs Institute to fund an early feasibility study in this area but discontinued our support as part of an initiative to reduce our operating expenses. For additional information, see “Workforce Reduction Initiative” below.
We consider our current addressable market for our CGuard EPS, CGuard Prime, and SwitchGuard NPS to be both symptomatic and asymptomatic individuals with diagnosed high-grade carotid artery stenosis for whom intervention is preferable to medical (drug) therapy. This group includes not only patients eligible for either CAS or TCAR procedures, but also individuals who are candidates for CEA, as all three approaches can be options to treat these patients. Assuming full penetration of the intervention caseload, we estimate that the addressable market for CGuard EPS, CGuard Prime, and SwitchGuard NPS is approximately $1.3 billion (source: Health Research International Personal Medical Systems, Inc. September 13, 2021 Results of Update Report on Global Carotid Stenting Procedures and Markets by Major Geography and Addressable Markets and internal estimates). According to this same report and internal estimates, assuming full penetration of treatment for all individuals diagnosed with high-grade carotid artery stenosis, we estimate the total available market for CGuard EPS, CGuard Prime, and SwitchGuard NPS to be approximately $9.3 billion, which may grow over time if expanded treatment options such as our products lead to increased patient screening for carotid artery disease.
| 4 |
FDA Matters
In May 2026, we announced a voluntary recall in the U.S. of the CGuard Prime 135 cm product, initiated in consultation with the FDA. The Company acted after determining during a controlled launch that the technical success rate of the CGuard Prime 135 cm delivery system had not met performance expectations. The voluntary action was limited to the CGuard Prime 135 cm delivery system and did not involve the CGuard stent implant. Our assessment did not identify new safety concerns for patients who had previously received a CGuard implant. We believe we have identified the root cause of the performance-related issues that caused the recall and are implementing design modifications intended to address them. We are currently performing verification and validation testing of these modifications in support of a PMA supplement to the FDA which we expect to submit in the fourth quarter of 2026. We cannot provide any assurance that the FDA will be satisfied with the corrective actions we are implementing in connection with the voluntary recall, or as to the timing of the resolution of such issues. Until these issues are resolved to the FDA’s satisfaction, we may be unable to resume commercialization of CGuard Prime 135 cm in the United States. If the FDA determines that our corrective actions are inadequate or requires additional remediation, testing, validation or regulatory submissions, such requirements could increase costs, delay or prevent FDA acceptance or approval of our proposed PMA supplement, extend the duration of the voluntary recall, delay our ability to reintroduce CGuard Prime 135 cm to the U.S. market or otherwise adversely affect our future commercialization plans, which could have a material adverse effect on our business, financial condition and results of operations. As of September 30, 2026, all affected products were returned, and credits were issued to customers. In the quarter ended June 30, 2026, we recorded approximately $734,000 as a reduction of revenue related to these returns and approximately $612,000 of inventory impairment associated with the recall. No additional revenue reductions or inventory impairment charges related to the recall were recorded during the quarter ended September 30, 2026.
Workforce Reduction Action
During the quarter ended September 30, 2026, we completed a workforce reduction (the “Q3’26 Workforce Reduction”) as part of a broader initiative to reduce our operating expenses, improve operational efficiency and better align our resources with our strategic priorities. The Q3’26 Workforce Reduction reduced the number of positions in the organization by approximately 20%. We incurred aggregate restructuring charges of approximately $1.1 million, consisting primarily of employee severance and related employee termination costs and recorded a related liability of approximately $444 thousand in the accompanying consolidated financial statements as of September 30, 2026. We expect these actions to better align our resources with key product development, regulatory, clinical and commercialization priorities while reducing our overall operating expense base.
Critical Accounting Policies
A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operations and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our critical accounting policies are more fully described in both (i) “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and (ii) Note 2 of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2025. There have not been any material changes to such critical accounting policies since December 31, 2025.
The currency of the primary economic environment in which our operations are conducted is the U.S. dollar (“$” or “dollar”).
Results of Operations
Three months ended September 30, 2026, compared to the three months ended September 30, 2025
Revenues. For the three months ended September 30, 2026, revenue was $2,242,000, a decrease of $281,000, or 11.1%, compared to $2,523,000 during the three months ended September 30, 2025. The decrease was primarily attributable to the voluntary recall of CGuard Prime 135 cm in the U.S. in May 2026, which was partially offset by revenues generated from continued growth in sales of CGuard EPS through distributors in international markets.
With respect to geographical regions, U.S. revenue was $32,000 for the three months ended September 30, 2026, which was derived from clinical trial activities, compared to $497,000 for the three months ended September 30, 2025. The decrease of $465,000 in U.S. revenue was primarily due to the voluntary recall of CGuard Prime 135 cm. This decrease was partially offset by growth of approximately 9% in international markets, with international revenue increasing to $2,210,000 for the three months ended September 30, 2026, compared to $2,026,000 for the three months ended September 30, 2025, including increases of $125,000 in Asia and $59,000 in all other regions, reflecting continued growth in demand in these markets.
| 5 |
Gross Profit. For the three months ended September 30, 2026, gross profit (revenue less cost of revenues) was $240,000 compared to $864,000 for the three months ended September 30, 2025, a decrease of $624,000. The decrease in gross profit was primarily attributable to adverse mix of revenue from the near absence of direct sales in the U.S. following the voluntary recall of CGuard Prime in May 2026, with U.S. revenue declining to $32,000 from $497,000 in the prior-year period. Revenue from direct sales in the U.S. carry higher unit profit due to a higher average selling price compared to sales to international distributors. In addition, we also experienced an adverse mix of sales within the international revenue, with a greater percentage of sales taking place to countries with lower average selling prices as compared to the prior year’s quarter.
Gross margin represents our gross profit as a percentage of revenue. Gross margin was 10.7% for the three months ended September 30, 2026, a decrease of 23.5 percentage points compared to gross margin of 34.2% for the three months ended September 30, 2025, primarily due to the factors discussed above.
Research and Development Expenses. For the three months ended September 30, 2026, research and development expenses were $3,273,000, a decrease of $362,000, or 10.0%, compared to $3,635,000 during the three months ended September 30, 2025. The decrease was primarily attributable to lower share-based compensation including the reversal of $443,000 of share-based compensation expense associated with forfeited equity awards following the Q3’26 Workforce Reduction and reduced spending on the TCAR and CGUARDIANS programs, partially offset by increased spending on the CGUARDIANS III clinical trial and clinical, regulatory and quality consulting support.
Selling and Marketing Expenses. For the three months ended September 30, 2026, selling and marketing expenses were $2,394,000, a decrease of $1,998,000, or 45.5%, compared to $4,392,000 during the three months ended September 30, 2025. This decrease resulted primarily from lower compensation and other personnel-related expenses following the implementation of our Q3’26 Workforce Reduction during the third quarter of 2026, including a decrease in share-based compensation expense due primarily to the reversal of $1,100,000 of expense associated with forfeited equity awards following the workforce reduction.
General and Administrative Expenses. For the three months ended September 30, 2026, general and administrative expenses were $3,452,000, a decrease of $2,436,000, or 41.4%, compared to $5,888,000 during the three months ended September 30, 2025. The decrease was primarily driven by lower compensation and personnel-related expenses, including the reversal of $280,000 of share-based compensation expense associated with forfeited equity awards following the Q3’26 Workforce Reduction and the inclusion in the prior-year period of severance and share-based compensation expenses of $220,000 and $721,000, respectively, associated with the departure of an executive.
Restructuring Expenses. For the three months ended September 30, 2026, restructuring expenses were $1,074,000 compared with no restructuring expenses in the three months ended September 30, 2025. The expenses primarily consisted of employee severance and related termination benefits associated with the workforce reduction initiative. See Note 6 to the condensed consolidated financial statements.
Financial Income. For the three months ended September 30, 2026, financial income was $191,000 compared to financial income of $343,000 during the three months ended September 30, 2025, representing a decrease of $152,000, or 44.3%. The decrease in financial income resulted primarily from lower income from investments in marketable securities and money market funds, partially offset by higher financial income related to changes in exchange rates.
Tax Expenses. We did not incur any tax expenses during the three months ended September 30, 2026 and September 30, 2025.
Net Loss. For the three months ended September 30, 2026, our net loss was $9,762,000, a decrease of $2,946,000, or 23.2%, compared to $12,708,000 during the three months ended September 30, 2025. The decrease in net loss resulted primarily from a decrease in total operating expenses of $3,722,000, partially offset by a decrease in gross profit of $624,000 and a decrease in financial income of $152,000 compared to the prior-year period.
Nine months ended September 30, 2026, compared to the nine months ended September 30, 2025
Revenues. For the nine months ended September 30, 2026, revenue was $7,411,000, an increase of $1,581,000, or 27.1%, compared to $5,830,000 during the nine months ended September 30, 2025. The increase was driven mainly by continued growth in sales of CGuard EPS through distributors in international markets and direct sales of CGuard Prime 135 cm in the U.S. prior to the voluntary recall. The increase was partially offset by $734,000 of credits issued in connection with the voluntary recall of CGuard Prime 135 cm in the U.S. during the nine months ended September 30, 2026.
| 6 |
With respect to geographical regions, U.S. revenue was $859,000 for the nine months ended September 30, 2026, compared to $551,000 for the nine months ended September 30, 2025. The increase of approximately $308,000 was driven by commercial sales of CGuard Prime 135 cm, partially offset by credits issued in connection with the voluntary recall of CGuard Prime 135 cm in May 2026. International revenue was $6,552,000 for the nine months ended September 30, 2026, compared to $5,279,000 for the nine months ended September 30, 2025. Revenue from international markets grew by $1,273,000, or 24.1%, including increases of $638,000 in Europe, $308,000 in Latin America, $215,000 in Asia, and $110,000 in all other regions. The international sales performance reflects continued growth in demand in these markets.
Gross Profit. For the nine months ended September 30, 2026, gross profit (revenue less cost of revenues) was $153,000 compared to gross profit of $1,469,000 for the nine months ended September 30, 2025. The decrease in gross profit was primarily attributable to the voluntary recall of CGuard Prime 135 cm in the U.S., including $734,000 of net credits issued to customers, which reduced revenue, as well as inventory impairment and inventory obsolescence charges totaling $1,085,000 related to the CGuard Prime 135 cm delivery system, which increased cost of revenues. These impacts were partially offset by the year-over-year increase in revenue.
Gross margin represents our gross profit as a percentage of revenue. Gross margin was 2.1% for the nine months ended September 30, 2026, a decrease of 23.1 percentage points compared to gross margin of 25.2% for the nine months ended September 30, 2025, primarily due to the factors discussed above.
Research and Development Expenses. For the nine months ended September 30, 2026, research and development expenses were $12,331,000, an increase of $803,000, or 7.0%, compared to $11,528,000 during the nine months ended September 30, 2025.
The increase was primarily driven by higher clinical trial expenses related to the initiation of the CGUARDIANS III pivotal trial and higher payroll expenses in connection with our expansion in the United States. These increases were partially offset by lower share-based compensation expense, including the reversal of $443,000 of share-based compensation expense associated with forfeited equity awards following the Q3’26 Workforce Reduction and lower clinical trial expenses following the completion of the CGUARDIANS I and CGUARDIANS II pivotal trials.
Selling and Marketing Expenses. For the nine months ended September 30, 2026, selling and marketing expenses were $12,795,000, an increase of $1,481,000, or 13.1%, compared to $11,314,000 during the nine months ended September 30, 2025. This increase resulted primarily from higher commercial staffing levels following the commercial launch of CGuard Prime 135 cm in the U.S. in July 2025. The increase was partially offset by lower compensation and other personnel-related costs following the implementation of our Q3’26 Workforce Reduction, including a decrease in share-based compensation expense due primarily to the $1,100,000 reversal of share-based compensation expense associated with forfeited equity awards following the workforce reduction.
General and Administrative Expenses. For the nine months ended September 30, 2026, general and administrative expenses were $12,329,000, a decrease of $3,828,000, or 23.7%, compared to $16,157,000 during the nine months ended September 30, 2025. The decrease was primarily driven by lower compensation and personnel-related expenses, including the reversal of $280,000 of share-based compensation expense associated with forfeited equity awards following the Q3’26 Workforce Reduction and the inclusion in the prior-year period of severance and share-based compensation expenses of $575,000 and $1,554,000, respectively, associated with the departure of an executive.
Restructuring Expenses. For the nine months ended September 30, 2026, restructuring expenses were $1,074,000 compared with no restructuring expenses in the nine months ended September 30, 2025. The expenses primarily consisted of employee severance and related termination benefits associated with the workforce reduction initiative. See Note 6 to the condensed consolidated financial statements.
Financial Income. For the nine months ended September 30, 2026, financial income was $601,000, an increase of $96,000, or 19.0%, compared to $505,000 during the nine months ended September 30, 2025. The increase in financial income resulted primarily from lower financial expenses related to changes in exchange rates, partially offset by lower income from investments in marketable securities and money market funds.
| 7 |
Tax Expenses. We did not incur any tax expenses during the nine months ended September 30, 2026 and September 30, 2025.
Net Loss. For the nine months ended September 30, 2026, our net loss was $37,775,000, an increase of $750,000, or 2.0%, compared to $37,025,000 during the nine months ended September 30, 2025. The increase in net loss resulted primarily from a decrease in gross profit of $1,316,000, partially offset by a decrease in total operating expenses of $470,000 (including restructuring expenses of $1,074,000) and an increase in financial income of $96,000 compared to the prior-year period.
Liquidity and Capital Resources
We had an accumulated deficit as of September 30, 2026, of $340 million, as well as a net loss of $38 million for the nine months ended September 30, 2026, and negative operating cash flows. We expect to continue incurring losses and negative cash flows from operations until we expand our commercial revenue to a scale that funds our commercial resources, development activities and support functions. As a result of these expected losses and negative cash flows from operations, along with our current cash position, we believe we do not have sufficient resources to fund operations for at least the next 12 months from the date of issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. Therefore, there is substantial doubt about our ability to continue as a going concern.
On November 16, 2026, we closed the November 2026 Offering (as defined below) resulting in gross proceeds of approximately $37.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. For additional information, see “November 2026 Public Offering” below.
Our plans include continued commercialization of our products and raising capital through the sale of additional equity securities, debt financing, capital inflows from strategic partnerships and the exercise of outstanding warrants. There can be no assurance, however, that we will be successful in obtaining the level of financing needed for our operations. If we are unsuccessful in commercializing our products or raising capital, we may need to reduce, curtail or cease operations.
In May 2023, we closed a private placement offering that resulted in aggregate gross proceeds of approximately $42.2 million, before deducting fees payable to the placement agent and other offering expenses payable by us, pursuant to which we issued and sold 10,266,270 shares of our common stock, pre-funded warrants to purchase up to 15,561,894 shares of common stock and warrants to purchase up to an aggregate of 51,656,328 shares of common stock, consisting of Series H warrants to purchase up to 12,914,086 shares of common stock (the “Series H Warrants”), Series I warrants to purchase up to 12,914,078 shares of common stock (the “Series I Warrants”), Series J warrants to purchase up to 12,914,086 shares of common stock (the “Series J Warrants”) and Series K warrants to purchase up to 12,914,078 shares of common stock (the “Series K Warrants” and, together with the Series H Warrants, Series I Warrants and Series J Warrants, the “May 2023 Warrants”), at an offering price of $1.6327 per share of common stock and associated May 2023 Warrants and an offering price of $1.6326 per pre-funded warrant and associated May 2023 Warrants.
On September 21, 2026, we entered into amendments (the “Warrant Amendments”) with certain holders of outstanding May 2023 Warrants. Pursuant to the Warrant Amendments, we amended Series J Warrants to purchase up to 4,771,980 shares of common stock and Series K Warrants to purchase up to 9,543,947 shares of common stock to modify (i) the exercise price to $0.7674 per share and (ii) the termination date to 5:00 p.m. Eastern time on the earlier of (a) May 15, 2028 and (b) 20 trading days following our announcement of receipt of FDA approval of the CGuard Prime 80 cm. The Series J Warrants that were not amended, consisting of Series J Warrants to purchase up to 8,142,106 shares of common stock, have an exercise price of $1.3827 per share and a termination date of 5:00 p.m. Eastern time on the earlier of (a) May 15, 2028 and (b) 20 trading days after FDA approval of SwitchGuard NPS and the CGuard Prime 80 cm. The Series K Warrants that were not amended, consisting of Series K Warrants to purchase up to 3,370,131 shares of common stock, had an exercise price of $1.3827 per share and a termination date of 5:00 p.m. Eastern time on October 28, 2026, which was 20 trading days after the end of the fourth fiscal quarter following the commencement of first U.S. commercial sales of CGuard Prime 135 cm in July 2025 and expired unexercised on such date. The Series K Warrants that were amended pursuant to the Warrant Amendments and the Series J Warrants will expire on December 11, 2026, unless exercised prior to that date, which is 20 trading days after our announcement of receipt of the PMA for CGuard Prime 80 cm for use in TCAR procedures.
If the May 2023 Warrants, as amended, are exercised in cash in full, the aggregate gross proceeds would be approximately $57.9 million (of which approximately $35.7 million has been received as of the date of this Quarterly Report on Form 10-Q). There can be no assurance that we will achieve any of the remaining milestones set forth in the outstanding May 2023 Warrants or that the outstanding May 2023 Warrants will be exercised in cash in full. The last reported sale price of our common stock on November 13, 2026 was $0.64 per share. We believe that the likelihood that warrant holders will exercise their outstanding May 2023 Warrants, and therefore the amount of cash proceeds we would receive, is dependent upon the trading price of our common stock. If the trading price of our common stock is less than $1.3827 per share with respect to the May 2023 Warrants that were not amended or $0.7674 per share with respect to the May 2023 Warrants that were amended, we believe that warrant holders will be unlikely to exercise their outstanding May 2023 Warrants.
| 8 |
Following the announcement of the one-year follow-up results from our CGUARDIANS pivotal trial, the Series H Warrants were exercised in full for 292,996 shares of common stock and pre-funded warrants to purchase 12,621,090 shares of common stock. The net proceeds from the exercise of the Series H Warrants were $16.9 million after deducting placement agent fees.
Following the announcement of the FDA’s premarket approval of CGuard Prime, the Series I Warrants were exercised in full for 2,352,393 shares of common stock and pre-funded warrants to purchase 10,561,685 shares of common stock during June and July 2025. The net proceeds from the exercise of the Series I Warrants were $16.9 million after deducting placement agent fees.
In May 2024, we entered into an Equity Distribution Agreement (the “2024 Distribution Agreement”) with Piper Sandler & Co., as sales agent (“Piper Sandler”). Pursuant to the 2024 Distribution Agreement, we were able to offer and sell from time to time, at our option, through or to Piper Sandler shares of our common stock having an aggregate offering price of up to $75 million. We paid Piper Sandler a commission at a fixed rate of 3.0% of the aggregate gross proceeds from each sale of the shares under the 2024 Distribution Agreement. On April 3, 2026, we terminated the 2024 Distribution Agreement in connection with our entry into the 2026 Distribution Agreement (as defined below) with BTIG (as defined below). During the nine months ended September 30, 2026, we did not sell any shares pursuant to the 2024 Distribution Agreement.
In August 2025, we closed a private placement offering that resulted in aggregate gross proceeds of approximately $40.1 million, before deducting fees payable to the placement agent and other offering expenses payable by us.
In April 2026, we entered into an Equity Distribution Agreement (the “2026 Distribution Agreement”) with BTIG, LLC, as sales agent (“BTIG”). Pursuant to the 2026 Distribution Agreement, we may offer and sell from time to time, at our option, through or to BTIG shares of our common stock having an aggregate offering price of up to $75 million. We will pay BTIG a commission of up to 3.0% of the aggregate gross proceeds from each sale of the shares under the 2026 Distribution Agreement. As of the date of this Quarterly Report on Form 10-Q, we have not sold any shares pursuant to the 2026 Distribution Agreement.
November 2026 Public Offering
On November 13, 2026, we entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “November 2026 Offering”) of (i) 7,342,308 shares of our common stock, and pre-funded warrants to purchase up to 50,350,000 shares of our common stock (the “November 2026 Pre-Funded Warrants”), and (ii) accompanying Series L warrants to purchase up to 43,269,231 shares of our common stock (or, at the election of the holder, November 2026 Pre-Funded Warrants to purchase up to an equal number of shares of our common stock in lieu thereof) (the “Series L Warrants” and, together with the November 2026 Pre-Funded Warrants, the “November 2026 Warrants”), representing 75% of the aggregate number of shares of common stock and November 2026 Pre-Funded Warrants sold in the November 2026 Offering. Each share of our common stock is being sold together with an accompanying Series L Warrant at a combined public offering price of $0.65, and each November 2026 Pre-Funded Warrant is being sold together with an accompanying Series L Warrant at a combined public offering price of $0.6499, which equals the combined public offering price per share of our common stock and accompanying Series L Warrant, minus $0.0001.
The November 2026 Offering closed on November 16, 2026. The gross proceeds from the November 2026 Offering were approximately $37.5 million, and we estimate that the gross proceeds from the November 2026 Offering will be approximately $43.1 million if the Representative exercises its option to purchase additional securities in full (as further described below), in each case, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the Warrants.
Each Series L Warrant has an exercise price of $0.65 per share of our common stock, is immediately exercisable upon issuance, will expire one year from the date of issuance and may be exercised, at the holder’s election, for pre-funded warrants in lieu of shares of our common stock. If the Series L Warrants are exercised in cash in full, the aggregate gross proceeds would be approximately $28.1 million. There can be no assurance that the outstanding Series L Warrants will be exercised in cash in full.
Each November 2026 Pre-Funded Warrant has an exercise price of $0.0001 per share of our common stock, is immediately exercisable upon issuance and may be exercised at any time until exercised in full. A holder may not exercise any portion of its November 2026 Warrants to the extent that the holder, together with its affiliates and attribution parties, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding common stock immediately after exercise.
We also granted the Representative a 30-day option to purchase up to 8,653,846 additional shares of our common stock and/or pre-funded warrants to purchase up to 8,653,846 shares of our common stock and/or Series L Warrants to purchase up to 6,490,384 shares of our common stock (or pre-funded warrants in lieu thereof) (or any combination thereof) at the applicable public offering price minus underwriting discounts and commissions, representing 15% of the total number of shares of our common stock, November 2026 Pre-Funded Warrants and Series L Warrants sold in the November 2026 Offering, solely to cover over-allotment, if any. As of the date hereof, the Representative has not exercised this option, and there can be no assurance that the Representative will exercise the option, in whole or in part.
| 9 |
Nine months ended September 30, 2026, compared to the nine months ended September 30, 2025
General. As of September 30, 2026, we had cash and cash equivalents of $19,246,000 as compared to cash and cash equivalents of $8,939,000 and marketable securities of $45,272,000 as of December 31, 2025. We have historically met our cash needs through a combination of issuing new shares, borrowing activities and product sales. Our cash requirements are generally for research and development, marketing and sales activities, finance and administrative costs, capital expenditures and general working capital.
For the nine months ended September 30, 2026, net cash used in our operating activities increased by $8,102,000, or 31.5%, to $33,860,000, from $25,758,000 during the same period in 2025. The primary reasons for the increase in cash used in our operating activities were an increase of $6,660,000 in compensation costs paid during the nine months ended September 30, 2026 (from $17,843,000 in the nine months ended September 30, 2025 to $24,503,000 in the nine months ended September 30, 2026) and an increase of $4,041,000 in payments to vendors, clinical service providers and other professional service providers, partially offset by an increase of $2,455,000 in payments received from customers during the nine months ended September 30, 2026 (from $5,591,000 in the nine months ended September 30, 2025 to $8,046,000 during the nine months ended September 30, 2026).
Cash provided by our investing activities was $44,157,000 during the nine months ended September 30, 2026, compared to $14,575,000 during the nine months ended September 30, 2025. The primary reason for the increase in cash provided by our investing activities was the receipt of $45,000,000 in proceeds from matured marketable securities.
There was no cash provided by financing activities for the nine months ended September 30, 2026. Cash provided by financing activities for the nine months ended September 30, 2025 was $55,569,000. The sources of cash provided by financing activities during the nine months ended September 30, 2025 were approximately $38,714,000 of aggregate net proceeds from our private placement offering in August 2025 and sales of common stock under the 2024 Distribution Agreement, and $16,855,000 of proceeds from the exercise of Series I Warrants.
Off-Balance Sheet Arrangements
We have no off-balance sheet transactions, arrangements, obligations (including contingent obligations) or other relationships with unconsolidated entities or other persons that have, or may have, a material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
Factors That May Affect Future Operations
We believe that our future operating results will continue to be subject to quarterly variations based upon a wide variety of factors, including market acceptance of our products, the timing of the resumption of U.S. commercialization of CGuard Prime following the voluntary recall, the cyclical nature of the ordering patterns of our distributors, the timing of regulatory approvals, the implementation of various phases of our clinical trials, manufacturing efficiencies due to the learning curve of utilizing new materials and equipment and the costs or other consequences associated with any current or future product recall. Product recalls in particular have adversely affected and may continue to adversely affect our operating results through the direct costs of executing a recall, lost revenues resulting from the removal of affected products from the market and the interruption of sales during any remediation period, costs associated with redesigning and remanufacturing affected products, potential regulatory, litigation and other legal costs, and longer-term reputational harm that may reduce market acceptance of our current and future products. Our operating results could also be impacted by a weakening of the euro and a strengthening of the New Israeli Shekel (“NIS”), each against the U.S. dollar. Lastly, other economic conditions we cannot foresee may affect customer demand, such as individual country reimbursement policies pertaining to our products.
Contractual Obligations and Commitments
During the nine months ended September 30, 2026, there were no material changes to our contractual obligations and commitments since the year ended December 31, 2025.
Recently Adopted and Issued Accounting Pronouncements
See Note 3 to our condensed financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not applicable.
Item 4. Controls and Procedures
Management’s Conclusions Regarding Effectiveness of Disclosure Controls and Procedures
As of September 30, 2026, we conducted an evaluation, under the supervision and participation of management including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Securities Exchange Act of 1934, as amended). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.
Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective at the reasonable assurance level as of September 30, 2026.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 2026, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 10 |
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. There are currently no pending material legal proceedings, and we are currently not aware of any legal proceedings or claims against us or our property that we believe will have any significant effect on our business, financial position or operating results.
Item 1A. Risk Factors
Except as set forth below in this Item 1A and the Risk Factors included in our previous filings made with the SEC, there have been no material changes to our risk factors from those disclosed in “Part I. Item 1A. Risk Factors” in the Form 10-K filed with the SEC on March 18, 2026.
Management has concluded that there is substantial doubt about our ability to continue as a going concern, and our condensed financial statements for the quarter ended September 30, 2026 includes an explanatory paragraph as to our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.
Because we have had recurring losses and negative cash flows from operating activities, substantial doubt exists regarding our ability to remain as a going concern at the same level at which we are currently performing. Accordingly, our condensed financial statements for the quarter ended September 30, 2026 includes an explanatory paragraph as to our potential inability to continue as a going concern. The doubts regarding our ability to continue as a going concern may adversely affect our ability to obtain new financing on reasonable terms or at all.
If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.
Nasdaq has established certain standards for the continued listing of a security on the Nasdaq Capital Market. The standards for continued listing include, among other things, that the minimum bid price for the listed securities not fall below $1.00 per share for a period of 30 consecutive trading days and that we maintain a minimum of $2,500,000 in stockholders’ equity.
On July 17, 2026, we received a notification letter, or the Notification Letter, from the Nasdaq Listing Qualifications notifying us that we are not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2), or the Rule, for continued listing on The Nasdaq Capital Market. The Notification Letter provides that we have 180 calendar days, or until January 13, 2027, to regain compliance with the Rule. To regain compliance, the bid price of our common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. In the event we do not regain compliance by January 13, 2027, we may then be eligible for an additional 180 days if we meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of our intention to cure the deficiency during the second compliance period. If we do not qualify for the second compliance period or fail to regain compliance during the second compliance period, then Nasdaq will notify us of its determination to delist our common stock, at which point we will have an opportunity to appeal the delisting determination to a Hearings Panel.
No assurance can be given that we will be able to regain compliance with the Rule. Failure to meet applicable Nasdaq continued listing standards could result in a delisting of our common stock. A delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and fewer business development opportunities.
| 11 |
Although we have completed our restructuring and associated workforce reduction, the restructuring may not result in the anticipated savings or operational efficiencies, may result in total costs and expenses that are greater than expected, and may disrupt our business.
We recently completed a restructuring plan that included a reduction in our workforce. We incurred costs and expenses in connection with the restructuring, and we may continue to incur additional costs and expenses related to the restructuring. In addition, our restructuring activities may subject us to reputational risks and litigation risks and expenses. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition would be adversely affected. In addition, to the extent we do not realize such anticipated operational efficiencies, we may need to undertake additional workforce reductions or restructuring activities in the future.
Furthermore, the effects of the restructuring may continue to be disruptive to our operations. For example, our workforce reductions could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and reduced employee morale. The changes to our operations and the reduction in workforce may yield unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond our intended reductions in force, and a reduction in morale among our remaining employees, all of which may have an adverse effect on our business, results of operations or financial condition. If employees who were not affected by the reductions in force seek alternative employment, this could result in our seeking contractor support at unplanned additional expense or harm our productivity. Any employee litigation related to the headcount reduction could be costly and prevent management from fully concentrating on the business.
The workforce reduction may adversely affect our ability to attract and retain qualified management, scientific, technical, and manufacturing personnel who are critical to our business. For example, the workforce reduction may negatively impact our regulatory, technical operations, and commercial functions, which could adversely affect our ability to successfully develop, and ultimately, commercialize our products. We may find that the workforce reduction makes it more difficult to pursue new opportunities and initiatives and may require us to hire qualified replacement personnel, resulting in additional costs and expenses. Our future financial performance and our ability to develop our products or additional assets will depend, in part, on our ability to effectively manage any future growth or restructuring, as the case may be. Our failure to successfully accomplish any of the above activities and goals may have a material adverse impact on our business, results of operations and financial condition.
Our products have been, and may in the future be, subject to product notifications, recalls, or voluntary market withdrawals that could harm our reputation, business and financial results.
After regulatory approval has been obtained for medical device products, the product and the manufacturer are subject to continual review, including the review of adverse events and clinical results that are reported after our products are made available to patients, and there can be no assurance that such approval will not be withdrawn or restricted. Regulators may also subject approvals to restrictions or conditions or impose post-approval obligations on the holders of these approvals, and the regulatory status of such products may be jeopardized if such obligations are not fulfilled. If post-approval studies are required, such studies may involve significant time and expense.
The manufacturing and marketing of medical devices involves an inherent risk that our products may prove to be defective and cause a health risk even after regulatory clearances have been obtained. The FDA and similar governmental authorities in other countries have the authority to require the recall of commercialized products in the event of material regulatory deficiencies or defects in design or manufacture. Medical devices may also be modified after regulatory clearance is obtained to such an extent that additional regulatory clearance is necessary before the device can be further marketed. In these events, we may voluntarily implement a recall or market withdrawal or may be required to do so by a regulatory authority. For example, in May 2026, we announced a voluntary recall in the U.S. of CGuard Prime 135 cm, initiated in consultation with the FDA. This decision followed our determination during controlled launch that the technical success of the delivery system had not met performance expectations. Such recall, and any recalls in the future, could result in significant current and future costs and other negative impacts associated with such recalls (including inventory write-off costs, refunds), loss of revenues, sales or customers, potential actions by regulators or other governmental entities, potential claims and lawsuits by customers and patients (including class action product liability litigation), other operational impacts and consequences such as business disruption, loss of personnel and distraction of management or other key employees, the restatement of previously issued financial statements, inability to raise capital, as well as negative publicity and damage to our reputation, which could have a material adverse impact on our business, results of operations and financial condition.
| 12 |
In the European Economic Area, we must comply with the medical device vigilance system under Regulation (EU) 2017/745 on medical devices, or the MDR. Under this system, manufacturers are generally required to report serious incidents involving medical devices via an electronic system incorporated into the EU database on medical devices, called EUDAMED. Furthermore, manufacturers are required to take Field Safety Corrective Actions (“FSCAs”) to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed on the market. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices. FSCAs must be reported to the relevant competent authorities, even if the FSCA was undertaken in a third country in relation to a device which is also legally made available on the Union market and the reason for the FSCA is not limited to the device made available in the third country.
Any adverse event involving our products could result in other future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Adverse events have been reported to us in the past, and we cannot guarantee that they will not occur in the future. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, would require the dedication of our time and capital, distract management from operating our business and could harm our reputation and financial results.
Defects or failures associated with our products have led to recalls, and could lead to additional recalls, safety alerts or litigation, as well as significant costs and negative publicity.
Our business is subject to significant risks associated with the manufacture, distribution and use of medical devices that are placed inside the human body, including the risk that patients may be severely injured by or even die from the misuse or malfunction of our products caused by design flaws or manufacturing defects. In addition, component failures, design defects, off-label uses or inadequate disclosure of product-related information could also result in an unsafe condition or the injury or death of a patient. These problems could lead to a recall or market withdrawal of, or issuance of a safety alert relating to, our products and could result in significant costs, negative publicity and adverse competitive pressure. For example, in May 2026, we announced a voluntary recall in the U.S. of CGuard Prime 135 cm, initiated in consultation with the FDA. This decision followed our determination during the controlled launch that the technical success of the delivery system had not met performance expectations. The circumstances giving rise to recalls are unpredictable, and any recalls of existing or future products increase the probability of inspection by, or additional scrutiny from, the FDA and could have a material adverse effect on our business, financial condition and results of operations.
The medical device industry has historically been subject to extensive litigation over product liability claims. Operating in the area of the neck with the brain as the end organ is dangerous and presents risks of adverse events such as bleeding, arterial dissection, cranial nerve injury, myocardial infarction, stroke and death, which subject us to a greater risk of being involved in litigation than companies with products used in less critical areas of the body. We may be subject to product liability claims if our products cause, or merely appear to have caused, an injury or death, even if due to physician error. In addition, an injury or death that is caused by the activities of our suppliers, such as those that provide us with components and materials, or by an aspect of a treatment used in combination with our products, such as a complementary drug or anesthesia, may be the basis for a claim against us by patients, hospitals, physicians or others purchasing or using our products, even if our products were not the actual cause of such injury or death. We may choose to settle any claims to avoid fault and complication, not due to failure of our products. An adverse outcome involving one of our products could result in reduced market acceptance and demand for all of our products and could harm our reputation and our ability to market our products in the future. In some circumstances, adverse events arising from or associated with the design, manufacture or marketing of our products could result in the suspension or delay of regulatory reviews of our premarket notifications or applications for marketing. Any of the foregoing problems could disrupt our business and have a material adverse effect on our business, financial condition and results of operations.
| 13 |
Although we carry product liability insurance in the United States and in other countries in which we conduct business, including for clinical trials and product marketing, we can give no assurance that such coverage will be available or adequate to satisfy any claims. Product liability insurance is expensive, subject to significant deductibles and exclusions, and may not be available on acceptable terms, if at all. If we are unable to obtain or maintain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect against potential product liability claims, we could be exposed to significant liabilities. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could have a material adverse effect on our business, financial condition and results of operations. Defending a suit, regardless of its merit or eventual outcome, could be costly, could divert management’s attention from our business and might result in adverse publicity, which could result in reduced acceptance of our products in the market, product recalls or market withdrawals.
We are required to file adverse event reports under MDR and regulations with the FDA, which reports are publicly available on the FDA’s website. We are required to file MDRs if our products may have caused or contributed to a serious injury or death or malfunctioned in a way that could likely cause or contribute to a serious injury or death if it were to recur. Any such MDR that reports a significant adverse event could result in negative publicity, which could harm our reputation and future sales.
Even if products we develop receive marketing approval, we or others may later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, which could compromise our ability or that of any collaborators to market the product, and could cause regulatory authorities to take certain regulatory actions, which could harm our commercial operations.
It is possible that our clinical trials may indicate an apparent positive effect of a product that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. For example, we or others may discover that our products are less safe or effective than previously believed. If we or others discover that a product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:
| ● | regulatory authorities may withdraw their approval of the product or seize the product; | |
| ● | we, or any of our collaborators, may be required to recall the product, change the way the product is administered or conduct additional clinical trials; |
| ● | additional restrictions may be imposed on the marketing of, or the manufacturing processes of, the particular product; | |
| ● | we, or any of our collaborators, may be subject to fines, injunctions or the imposition of civil or criminal penalties; | |
| ● | regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication including with the product; | |
| ● | we, or any of our collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients; | |
| ● | we could be sued and held liable for harm caused to patients; | |
| ● | physicians and patients may stop using our product; and | |
| ● | our reputation may suffer. |
Any of these events could harm our business and operations and could negatively impact our stock price.
For example, in May 2026, we announced a voluntary recall in the U.S. of CGuard Prime 135 cm, initiated in consultation with the FDA. This decision followed our determination during the controlled launch that the technical success of the delivery system had not met performance expectations. Such recall, and any recalls in the future, could result in significant current and future costs and other negative impacts associated with such recalls (including inventory write-off costs and refunds), loss of revenues, sales or customers, potential actions by regulators or other governmental entities, potential claims and lawsuits by customers and patients (including class action product liability litigation), other operational impacts and consequences such as business disruption, loss of personnel and distraction of management or other key employees, the restatement of previously issued financial statements, inability to raise capital, as well as negative publicity and damage to our reputation, which could have a material adverse impact on our business, results of operations and financial condition.
| 14 |
Material modifications to our products may require new 510(k) clearances, premarket approval, or CE Marks, or may require us to recall or cease marketing our products until new clearances or approvals are obtained.
Material modifications to the intended use or technological characteristics of our products will require new 510(k) clearances, premarket approvals (“PMA”) by the FDA or CE Marks under the EU Medical Device Regulation (“MDR”) prior to implementing the modifications, or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained. Furthermore, changes to our manufacturing facility or supplier of components used in our products require prior FDA approval of a PMA supplement. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance; however, the FDA can review a manufacturer’s decision. Any modification to an FDA cleared device that would significantly affect its safety or effectiveness or that would constitute a major change in its intended use would require a new 510(k) clearance or approval of a PMA supplement. We may not be able to obtain additional 510(k) clearances or premarket approvals for new products or for modifications to, or additional indications for, our products in a timely fashion, or at all. Delays in obtaining required future clearances would harm our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth. We have made modifications to our products in the past that we believe do not require additional clearances or approvals, and we may make additional modifications in the future. If the FDA or an EU Notified Body disagrees and requires new clearances or approvals for any of these modifications, we may be required to recall and to stop selling or marketing our products as modified, which could harm our operating results and require us to redesign our products. In these circumstances, we may be subject to significant enforcement actions. In response to the voluntary recall in the U.S. of CGuard Prime 135 cm, initiated in consultation with the FDA in May 2026, we intend to implement design improvements to CGuard Prime 135 cm. However, there can be no assurance that such design improvements will be sufficient to obtain FDA approval, or that any such approval will be obtained in a timely manner, if at all.
We bear the risk of warranty claims on our products.
We may not be successful in claiming recovery under any warranty or indemnity provided to us by our suppliers or vendors in the event of a successful warranty claim against us by a customer, and any recovery from such supplier or vendor may not be adequate. Furthermore, we may not have any, or have an adequate, warranty provided by our supplier. In addition, warranty claims brought by our customers related to third-party components may arise after our ability to bring corresponding warranty claims against such suppliers expires, which could result in costs to us. In addition, we have been, and in the future could be, subject to costs related to product recalls, and we could incur significant costs to correct any defects, warranty claims or other problems. Any such events could adversely affect our business, financial condition and results of operations.
Changes to trade policy, including tariff and customs regulations, or failure to comply with such regulations may have an adverse effect on our reputation, business, financial condition and results of operations.
Changes in U.S. or international social, political, regulatory and economic conditions or in laws and policies governing trade, manufacturing, development and investment in the countries where we currently conduct our business could adversely affect our business, reputation, financial condition and results of operations. Changes or proposed changes in U.S. or other countries’ trade policies may result in restrictions and economic disincentives on international trade.
We currently manufacture, package and distribute all of our products, including CGuard Prime, which we commercially launched in the U.S. in July 2025 following FDA approval of the PMA in June 2025 and which is currently subject to the voluntary recall described above, at our own facility in Israel. To support our anticipated production growth following the commercialization of CGuard Prime, we have engaged Aptyx Interventional Systems (“Aptyx”) to expand our manufacturing capacity of CGuard Prime finished goods to full-scale production at its ISO Class 7 cleanroom facility in North Carolina. While we are in the process of establishing manufacturing operations in the U.S. with Aptyx, this transition will take time, and until it is operational, we expect to rely entirely on product shipments from Israel to the U.S. market.
| 15 |
The U.S. government has recently adopted, proposed and considered a variety of tariff measures and other trade restrictions affecting imports from numerous countries, and additional changes to U.S. trade policy remain under active consideration. The implementation, modification, suspension, expiration, extension or judicial review of existing or proposed tariffs and trade measures has created and may continue to create significant uncertainty for companies engaged in international manufacturing and cross-border commerce. In addition, new investigations under U.S. trade laws, changes to customs rules, import restrictions, sanctions or other trade-related measures could result in additional duties, restrictions or compliance obligations affecting imported products and components.
Because we currently manufacture our products in Israel and remain dependent on shipments from Israel to serve the U.S. market while we continue efforts to expand manufacturing capacity in the United States, changes in tariffs, customs duties, import regulations or other trade measures applicable to products imported into the United States could increase our costs, reduce our margins, disrupt our supply chain, adversely affect customer demand or require us to modify our manufacturing, sourcing or distribution strategies. We cannot predict the scope, duration or outcome of current or future trade actions, related legal challenges, or any retaliatory measures by affected countries. Any of these developments could have a material adverse effect on our business, financial condition and results of operations.
Tariffs, economic sanctions and other changes in U.S. trade policy have in the past and could in the future trigger retaliatory actions by affected countries, and certain foreign governments have instituted or are considering imposing retaliatory measures on certain U.S. goods. Further, any emerging protectionist or nationalist trends (whether regulatory- or consumer-driven) either in the United States or in other countries could affect the trade environment. Our business, like many other corporations, would be impacted by changes to the trade policies of the United States and foreign countries (including governmental action related to tariffs, international trade agreements, or economic sanctions). We cannot predict whether, and to what extent, trade policies will change in the future. If tariffs or other trade restrictions are imposed on products manufactured in Israel while we remain dependent on Israeli manufacturing, our cost of goods sold for the U.S. market may increase materially, which could negatively impact our gross margins and limit our pricing flexibility. Additionally, changes to trade agreements or customs regulations between the U.S. and Israel could increase lead times, introduce logistical complexities, or require modifications to our supply chain planning. These or similar trade-related developments may have a material adverse effect on our business, financial condition, and results of operations.
If there are significant shifts in the political, economic and military conditions in Israel and its neighbors, it could have a material adverse effect on our business operations and ability to reach profitability.
Although we are incorporated in the State of Delaware and our headquarters are in Miami, Florida, our current manufacturing facility, certain of our key personnel and one of our offices are located in Israel. Our business is directly affected by the political, economic and military conditions in Israel and its neighbors. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations active in the region, including Iran, Hamas (an Islamist terrorist militia and political group that controls the Gaza Strip), Hezbollah (an Islamist terrorist militia and political group based in Lebanon) and other terrorist organizations active in the region. These conflicts have involved missile strikes, hostile infiltrations and terrorism against civilian targets in various parts of Israel, which have negatively affected business conditions in Israel.
In recent years, Israel has been engaged in sporadic armed conflicts with Hamas in the Gaza Strip, with Hezbollah, an Islamist terrorist group that controls large portions of southern Lebanon, and with Iranian-backed military forces in Syria. In addition, Iran has threatened to attack Israel and may be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. On October 7, 2023, Hamas launched a series of attacks on civilian and military targets in southern and central Israel, to which the Israel Defense Forces responded. On October 9, 2025, Israel, Hamas, the United States and other countries in the region agreed to a framework for a ceasefire in Gaza between Israel and Hamas.
In addition, both Hezbollah and the Houthi movement attacked military and civilian targets in Israel, to which Israel responded, including through increased air and ground operations in Lebanon. In addition, the Houthi movement attacked international shipping lanes in the Red Sea, to which both Israel and the United States responded. While a ceasefire was brokered between Israel and Hezbollah in November 2024, in March 2026, hostilities resumed along Israel’s northern border with Lebanon, when Hezbollah resumed its attacks as part of a broader regional escalation. In response, Israel resumed military operations against Hezbollah in Lebanon.
| 16 |
Further, in April 2024 and October 2024, Iran launched a series of drone and missile strikes against Israel, to which Israel responded. In addition, in response to ongoing Iranian aggression and support of proxy attacks against Israel, on June 13, 2025, Israel conducted a series of preemptive defensive air strikes in Iran targeting Iran’s nuclear program and military commanders. While a ceasefire was reached in June 2025 following 12 days of hostilities, on February 28, 2026, the United States and Israel launched coordinated military strikes against Iran, including attacks on strategic military infrastructure and leadership targets, with the stated aim of degrading Iran’s capacity to conduct or support hostile operations against them. In response, Iran has fired missiles and drones toward population centers and military installations in Israel, Europe and neighboring countries in the Gulf region, and also launched counter-strikes against U.S. forces and allied bases throughout the Gulf region. Although the United States and Iran have announced ceasefire and de-escalation arrangements from time to time, including a memorandum of understanding entered into on June 17, 2026 that contemplates the termination of military operations on multiple fronts, hostilities have resumed and may continue or escalate. A broader regional conflict involving additional state and non-state actors remains a significant risk. The duration and severity of the conflicts in Gaza, northern Israel, Lebanon, Iran and the broader region are unknown at this time, and any renewed or continued clash among Israel, Hamas, Hezbollah, Iran or other countries or militant groups in the region may escalate in the future into a greater regional conflict. Continued military escalation, retaliatory actions, or broader regional involvement may adversely affect economic conditions, disrupt markets, and create uncertainty that could negatively impact our business, financial condition and results of operations.
Certain of our employees may be obligated to perform military reserve duty generally until they reach the age of 40 (or older, for officers or other citizens who hold certain positions in the Israeli armed forces reserves) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity and military conflicts in Israel, there have been periods of significant call-ups of military reservists. Military service call-ups that result in absences of personnel from us for an extended period of time may materially and adversely affect our business, prospects, financial condition and results of operations.
To date, our operations have not been adversely affected by this situation. We currently manufacture our CGuard EPS and CGuard Prime at our facility in Tel Aviv, Israel. If there were a disruption to our existing manufacturing facility or our ability to procure raw materials and ship our products, we would have no other means of manufacturing and distributing CGuard EPS or CGuard Prime until we were able to restore the manufacturing and distribution capability at our facility or develop alternative manufacturing facilities and distribution capabilities. However, the intensity and duration of the security situation in Israel have been difficult to predict, as are the economic implications on our business and operations and on Israel’s economy in general. If the current conflicts continue for a long period of time or expand to other fronts, our operations may be harmed.
Our commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.
The continued political instability and hostilities between Israel and its neighbors and any future armed conflict, terrorist activity or political instability in the region could adversely affect our operations in Israel and adversely affect the market price of our shares of common stock. In addition, several organizations and countries may restrict doing business with Israel and Israeli companies have been and are today subjected to economic boycotts. The interruption or curtailment of trade between Israel and its present trading partners could adversely affect our business, financial condition and results of operations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
| 17 |
Item 5. Other Information
During
the quarter ended September 30, 2026, no director or officer of the Company
Item 6. Exhibits
EXHIBIT INDEX
| Exhibit No. | Description | |
| 3.1 | Amended and Restated Certificate of Incorporation, as amended through September 30, 2015 (incorporated by reference to Exhibit 3.1 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2015) | |
| 3.2 | Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on June 29, 2021) | |
| 3.3 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 25, 2016) | |
| 3.4 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 29, 2016) | |
| 3.5 | Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 15, 2017) | |
| 3.6 | Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on November 29, 2017) | |
| 3.7 | Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on December 12, 2017) | |
| 3.8 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on February 7, 2018) | |
| 3.9 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 28, 2019) | |
| 3.10 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.17 to the Quarterly Report on Form 10-Q filed on May 10, 2021) | |
| 3.11 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 13, 2023) | |
| 3.12 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on June 3, 2026) | |
| 31.1* | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 31.2* | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 32.1* | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 32.2* | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 101.INS* | Inline XBRL Instance Document (the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document) | |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB* | Inline XBRL Taxonomy Extension Labels Linkbase Document | |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104* | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
* Filed herewith.
| 18 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| INSPIREMD, INC. | ||
| Date: November 16, 2026 | By: | /s/ Marvin Slosman |
| Name: | Marvin Slosman | |
| Title: | President and Chief Executive Officer (Principal Executive Officer) | |
| Date: November 16, 2026 | By: | /s/ Michael Lawless |
| Name: | Michael Lawless | |
| Title: | Chief Financial Officer (Principal Financial and Accounting Officer) | |
| 19 |